Biovest study backs non-Hodgkin

bengeyqafiba1640.blogspot.com
The study was featured at the ’zs annual meeting in Orlando, Biovest said in a release. It is a brighy spot for Biovest and itsparenty company, (PINK SHEETS: ABPIQ), whicuh filed for Chapter 11 bankruptcyu late last year. BiovaxID is a personalized therapeutifc anti-cancer vaccine individually manufactured from a tissue biopsy obtainecd froma patient’s own selectively targeting only the cancerous B-cells whilew sparing health cells. The study found that patientd who received BiovaxID experiencesd amedian disease-free survival of 44.2 month, comparef to 30.6 months for thoser who receive a control vaccine, an increase of 47 In follow-ups with a mediaj of 4.
7 years, patients receiving BiovaxID experienced a 38 percenyt lower risk of disease recurrencr compared to patients receiving the contro l vaccine. BiovaxID is the first vaccine targeting lymphom to demonstrate sucha disease-free survivap benefit, the release said. Biovest (PINK BVTI) has initiated discussions with the and the to determine the most appropriateregulatory pathways, Samuelp Duffey, president and general counsel of Biovest, said in the release. The companhy also plans to make the vaccind available throughout most of Europe through a compassionated use drug access program that allows European physicians to prescribe drugs to qualifying patient before approvalsare granted.
Both Accentiq (PINK SHEETS: ABPIQ), a drug development firm, and Biovest are headquarteredin Tampa.